Form S-3ASR REGENERON PHARMACEUTICAL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 13% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
November 1, 2024 7:19 AM EDTLeerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are reducing our REGN PT from $1,077 (22x old 2025E EPS of $48.96) to $880 (20x new 2025E EPS of $44.01). We... More
Regeneron (REGN) Files Mixed Shelf
October 31, 2024 4:37 PM EDTRegeneron (NASDAQ: REGN) has filed mixed shelf of:
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
October 31, 2024 4:35 PM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,170.00 (from $1,175.00) while maintaining a Outperform rating.
The analyst comments "Its been all tricks and no treats for REGN. Following todays 3Q print, shares are off another ~10%... More
